News, Insights, & Events

Events
The Bioprocessing Summit

For more than 10 years, The Bioprocessing Summit has been recognized as the premier forum for industry leaders to share the latest research in bioprocess R&D, scale-up, quality and analytics.

#ef9146
Events
The Need for Speed: Creating Value in a Devalued Biotech Market Webinar

Recently, Biopharma and Life Science companies are facing dramatic devaluations which have made a negative impact on private funding and have left growing companies navigating a series of complex decisions as their business grows. 

 

Listen in as SmartLabs Co-Founder/CBO, Seth Taylor, moderates a discussion with Todd Foley, Managing Director of MPM Capital, and Chad Cowen, CEO of Clade Therapeutics, on the current market and its implications for growing companies. 

Events
AALAS

The American Association for Laboratory Animal Science (AALAS) is a membership association of professionals employed around the world in academia, government, and private industry who are dedicated to the humane care and treatment of laboratory animals, as well as the quality research that leads to scientific gains

#ef9146
Events
Cell & Gene Meeting on the Mesa

The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

#ef9146
Member News
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas Medicine, Inc. EDIT is making good progress with the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.

#e28869
Press Releases and Publications
Rob Speyer, Marty Burger, Mary Ann Tighe Named To New NYC Life Sciences Real Estate Board

New York City has set up a new advisory panel of developers, brokers and investors to advise how the city's real estate can be leveraged to better serve and grow its nascent life sciences industry.

#1ca5b6
Member News
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations.

#e28869
Member News
Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

 Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at

#e28869
Events
Next Generation CAR & T Cell Therapies

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors

#ef9146
Member News
Orna Therapeutics Announces First-in-Class, Breakthrough Data Demonstrating Potential of Circular RNA Platform at ASGCT 2022

- Advances in oRNA expression and delivery enable pipeline of therapeutics across a diverse range of disease areas

- Lead is CAR program shows possibility of tumor eradication in preclinical animal models with promise of translation to non-human primates and patients

#e28869
Member News
2022 Category Winner for Innovation: CRISPR Therapeutics

The FOYA judging committee commends CRISPR for creating a flexible, digitally-enabled facility that can bring the promise of innovation to life.

#e28869
Member News
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

- Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers

- Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency of CUE-100 series platform

#e28869